Loading...
ESMO congresses2020-11-24T16:37:55+01:00

ESMO 2020 – Congress digest on Lung Cancer – virtual

Preface – ESMO 2020

Preface - ESMO 2020 Byoung Chul Cho, MD, PhD - Division of Medical Oncology, Yonsei Cancer Center - Yonsei University College of Medicine - Seoul, South Korea Dear Colleagues, The ESMO Virtual Congress 2020 has attracted more than 30,000 registrants from over 150 countries to whom content presented at more than 70 sessions has been made available. The 2,137 abstracts reported at the conference included 87 late breaking abstracts. Sessions were provided for 135 proffered papers, 195 mini ora

Immune checkpoint inhibition: chemotherapy-free regimens & new PD-1 inhibitors on the horizon

Immune checkpoint inhibition: chemotherapy-free regimens & new PD-1 inhibitors on the horizon Monotherapy versus chemotherapy Five-year update of KEYNOTE-024 Pembrolizumab as single agent for up to 35 cycles has been shown to be superior to 4 to 6 cycles of platinum-doublet chemotherapy in patients with metastatic non–small-cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) ≥ 50 % in the KEYNOTE-024 trial.

Determinants of treatment success in small-cell lung cancer

Determinants of treatment success in small-cell lung cancer Predictive characteristics in CASPIAN … The randomized, controlled, open-label, phase III CASPIAN trial has assessed first-line treatment with durva­lumab ± tremelimumab plus platinum/etoposide (EP) compared to EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC).

Innovative and established approaches for patients with uncommon mutations

Innovative and established approaches for patients with uncommon mutations CROWN: first-line use of ALK inhibitor lorlatinib The highly potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor lorlatinib has been widely approved for the treatment of patients with ALK-positive advanced NSCLC who have previously received ALK TKIs.

EGFR-targeted options in a changing treatment landscape

EGFR-targeted options in a changing treatment landscape Amivantamab plus lazertinib The combination of amivantamab, a bispecific antibody that targets both EGFR and MET, and the potent third-generation EGFR TKI lazertinib is being explored in patients with advanced NSCLC.

Interview – Malignant mesothelioma: implementation of immunotherapy-based standards

Interview – Malignant mesothelioma: implementation of immunotherapy-based standards Paul Baas, MD, PhD, Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands Which outcomes can be expected in European patients with malignant mesothelioma who receive the current standard treatment? After 4 to 6 courses of standard chemotherapy with platinum and pemetrexed, we can expect a median overall survival of around 15 or 16 months.

Interview – Exploring interactions between radiotherapy and the immune system

Interview – Exploring interactions between radiotherapy and the immune system Maarten Lambrecht, MD, PhD, Department of Oncology, KU Leuven – University of Leuven, Belgium The modulation of molecular pathways that determine the patient response to radiotherapy might contribute to improving patient outcomes. What insights have been gained to date in this field of research that may be relevant in the years to come? There is indeed a growing interest in the field of radiobiology a

DOWNLOADS

All downloads from ESMO  2020 Lung Cancer – virtual

ESMO 2020 Lung Cancer English Slide Kit

Slide Kit PD-1/PD-L1 and PARP inhibition in NSCLC

ESMO 2020 Lung Cancer English

Full report (english)

ESMO 2020 Lung Cancer Mandarin

Full report (mandarin)

The ESMO Virtual Congress 2020 has attracted more than 30,000 registrants from over 150 countries to whom content presented at more than 70 sessions has been made available.

Byoung Chul Cho • MD • PhD, Division of Medical Oncology, Yonsei Cancer Center – Yonsei University College of Medicine – Seoul, South Korea

ESMO 2020 – Congress digest advanced Solid Tumours – virtual

Milestones of PD-1 inhibition in gastric and esophageal cancer

Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and esophageal adenocarcinoma are substantial causes of cancer-related mortality worldwide and have poor 5-year overall survival (OS) when diagnosed at an advanced stage [1, 2].

Getting innovation from the laboratories into clinical practice

Getting innovation from the laboratories into clinical practice Andrés Cervantes, MD, PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain Which data presented at ESMO 2020 in the field of gastric cancer, gastro­eso­phageal junction adeno­carcinoma and esophageal cancer do you deem practice-changing? The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by

Ovarian cancer: taking PARP inhibition one step further

Ovarian cancer: taking PARP inhibition one step further Individualized dosing of niraparib Niraparib has been approved as maintenance treatment for patients with plat­inum-sensitive recurrent ovarian cancer (OC) based on the results of the NOVA trial [1]. The starting dose used in NOVA was 300 mg orally daily.

Novel combination approaches in various solid tumors

Novel combination approaches in various solid tumors Lenvatinib plus pembrolizumab The anti-angiogenic multikinase in­hibitor lenvatinib has been shown to ­exert immunomodulatory effects that enhance the anti-tumor activity of anti-PD-1 antibodies [1]. In the early-phase setting, lenvatinib plus pembrolizumab induced partial responses in patients with different tumor types [2].

DOWNLOADS

All downloads from ESMO 2020 Solid Tumours – virtual

ESMO 2020 Solid Tumours English

Full report (english)

ESMO 2020 Solid Tumours Mandarin

Full report (mandarin)

The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemo­therapy. For the first time, this was prolonged to more than 1 year due to the ­addition of checkpoint inhibition.

Andrés Cervantes • MD • PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain